RIFM symposium
This article was originally published in The Rose Sheet
Executive Summary
"Dermal Sensitization: The Current and Future State of the Science Surrounding This Important Endpoint" is slated to be held by the Research Institute for Fragrance Materials Nov. 7 during the American College of Toxicology annual meeting in Williamsburg, Va. Symposium will include presentation on skin sensitization predictive testing, dose-response relationships and potency assessment. RIFM Scientific Director Anne Marie Api, PhD, and Procter & Gamble Principal Scientist Pauline McNamee, PhD, are among the scheduled speakers...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.